From next-generation cell therapies and stem cell treatments to bioengineered human tissues, the clinical potential of regenerative medicine research is clear. What is at the cutting-edge of regenerative medicine in 2021, and are these complex products ready to break into the big leagues? Abi Millar highlights the best and brightest players in regenerative medicine.
In February this year, the biotech company Humacyte announced its decision to go public, marking its shift from a clinical-stage company to a commercial one. The company, which develops regenerative human tissues that can be implanted in any patient without the need for immunosuppressive drugs, is expected to hit the market with a value of $1.1bn.
“We believe our universally implantable regenerative human tissue will be a disruptive technology with the potential to transform medicine,” says Humacyte CEO Dr Laura Niklason.
“We are creating engineered off-the-shelf replacement tissue, which can be implanted in anyone. Longer term, the technology has the potential to create solutions for complex organ disease, including replacement bioengineered organs.”
Rather than going down the IPO route, the company chose to go public via a special purchase acquisition company (SPAC), Alpha Healthcare. This has allowed it to engage investors more thoroughly – educating them on the platform and its groundbreaking possibilities. It represents a benchmark in the field of regenerative medicine.
Read the rest of this article in the May 2021 edition of Pharma Technology Focus
Journalist portfolio 